Pharma
Stay updated with the latest happenings in the pharmaceutical industry. Get insights into drug development, innovations, regulatory updates, and emerging trends. Discover the advancements shaping the future of healthcare. Explore the world of pharma with our comprehensive coverage at Pharmtales.com.
![Breakthrough Discovery Unveils New Mechanism Behind Autoimmune Diseases, Shedding Light on B Cell Self-Reactivity](https://pharmtales.com/wp-content/uploads/2023/10/B-cells-turn-against-the-body-in-a-new-type-of-autoimmune-disease-scientists-discover-1.jpg)
Breakthrough Discovery Unveils New Mechanism Behind Autoimmune Diseases, Shedding Light on B Cell Self-Reactivity
In a groundbreaking revelation, scientists have uncovered a vital piece of the puzzle that elucidates the perplexing phenomenon of B ...
![mRNA vaccine nobel prize 2023, mRNA vaccine discovery and development, COVID-19 vaccine nobel prize, mRNA vaccine technology and benefits, Nobel Prize for medicine 2023 winners, mRNA vaccine pioneers and history, COVID-19 pandemic and mRNA vaccine response,](https://pharmtales.com/wp-content/uploads/2023/10/mRNA-vaccine-pioneers-won-the-Nobel-Prize-for-medicine-amid-COVID-19-pandemic.jpg)
mRNA vaccine pioneers won the Nobel Prize for medicine amid COVID-19 pandemic
Two visionary scientists, Dr. Katalin Karikó and Dr. Drew Weissman, have been honored with the prestigious Nobel Prize for their ...
![What is the new reimbursement law in Germany and how does it affect drug pricing and reimbursement. Find out more here.](https://pharmtales.com/wp-content/uploads/2023/10/How-Germanys-New-Reimbursement-Law-Is-Shaking-Up-the-Pharma-Industry-.jpg)
How Germany’s New Reimbursement Law Is Shaking Up the Pharma Industry
Germany is one of the largest and most influential pharmaceutical markets in Europe, with a population of over 80 million ...
![Agenus, balstilimab, CTLA-4/PD-1, botensilimab, AGEN2373, AGEN1571, AGEN1423](https://pharmtales.com/wp-content/uploads/2023/08/Agenus-Shifts-Focus-to-CTLA-4_PD-1-Combo-Treatment-Implementing-Layoffs-and-Pipeline-Refinement.jpg)
September Layoffs: A Recap Of Recent Workforce Reductions In Biotech And Pharma
The pharma industry has been facing various challenges in 2023, such as the aftermath of the COVID-19 pandemic, the rising ...
![Teva appoints Christine Fox as new US president and CEO](https://pharmtales.com/wp-content/uploads/2023/09/Teva-appoints-Christine-Fox-as-new-US-president-and-CEO.jpg)
Teva appoints Christine Fox as new US president and CEO
Teva Pharmaceuticals, under the leadership of its CEO Richard Francis, continues its transformation with the appointment of Christine Fox as ...
![venclexta multiple myeloma trial, venclexta trial results, venclexta label expansion, abbvie roche venclexta, venclexta progression free survival, venclexta blood cancer, venclexta failed endpoint,](https://pharmtales.com/wp-content/uploads/2023/09/Venclexta-fails-to-meet-primary-endpoint-in-multiple-myeloma-trial.jpg)
Venclexta fails to meet primary endpoint in multiple myeloma trial
AbbVie and Roche, pioneers in the field of leukemia treatments with Venclexta, faced a setback as their hopes to expand ...
![eli lilly whistleblower lawsuit, eli lilly manufacturing problems, eli lilly branchburg plant, eli lilly quality issues, eli lilly settlement, eli lilly former employee, eli lilly lawsuit branchburg,](https://pharmtales.com/wp-content/uploads/2023/09/Eli-Lilly-settles-Whistleblower-lawsuit-over-alleged-quality-issues.jpg)
Eli Lilly settles Whistleblower lawsuit over alleged quality issues
Settlement talks have been underway between pharmaceutical giant Eli Lilly and a former human resources officer, Amrit Mula, who blew ...
![ptc therapeutics layoffs, translarna loses eu approval, dmd drug ptc layoffs, translarna dmd drug eu loss, ptc cuts jobs dmd drug setback, translarna withdrawal europe, ptc dmd drug revenue loss,](https://pharmtales.com/wp-content/uploads/2023/09/PTC-cuts-jobs-as-Europe-withdraws-approval-for-its-DMD-drug.jpg)
PTC cuts jobs as Europe withdraws approval for its DMD drug
PTC Therapeutics has announced an expansion of its previously planned workforce reductions as European regulatory concerns cast a shadow over ...
![adlai therapeutics ipo, novartis abandoned cancer drug, adlai adl-001 phase 3 trial, novartis cancer drug revived by adlai, adlai ipo for colorectal cancer drug, novartis adl-001 dropped by adlai, adlai colorectal cancer drug ipo,](https://pharmtales.com/wp-content/uploads/2023/09/Adlai-revives-Novartis-abandoned-cancer-drug-raises-57.5M-in-IPO-to-fund-phase-3-trial.jpg)
Adlai revives Novartis’ abandoned cancer drug, raises $57.5M in IPO to fund phase 3 trial
Adlai Nortye has solidified its financial footing, paving the way to determine the fate of its strategic investment in an ...
![freestyle libre cgm and glp-1 therapy, abbott analysis on cgm and glp-1 ra, cgm and glp-1 improve diabetes outcomes, abbott freestyle libre cgm and glp-1 study, cgm and glp-1 increase medication adherence, abbott diabetes study on cgm and glp-1, freestyle libre cgm and glp-1 benefits,](https://pharmtales.com/wp-content/uploads/2023/09/Abbott-study-shows-FreeStyle-Libre-CGM-and-GLP-1-therapy-improve-diabetes-outcomes.jpg)
Abbott study shows FreeStyle Libre CGM and GLP-1 therapy improve diabetes outcomes
In the realm of diabetes management, a symbiotic relationship appears to be flourishing between Continuous Glucose Monitoring (CGM) technology and ...
![structure oral obesity drug results, obesity drug data collection error, structure postpones obesity drug data, oral obesity drug promising data, structure data collection mistake obesity drug data delay, structure obesity drug trial,](https://pharmtales.com/wp-content/uploads/2023/09/Structure-posts-promising-results-for-oral-obesity-drug-but-delays-further-data-due-to-error.jpg)
Structure posts promising results for oral obesity drug, but delays further data due to error
Structure Therapeutics has offered an initial glimpse into the effectiveness of its oral GLP-1 receptor agonist, reporting a notable 5% ...
![astrazeneca symbicort marketing breaches, symbicort ads endanger patients, astrazeneca fined for symbicort violations, symbicort marketing rules violations, astrazeneca asthma drug ads breaches, symbicort ads pose serious risk, astrazeneca symbicort ads complaints,](https://pharmtales.com/wp-content/uploads/2023/09/AstraZeneca-fined-for-misleading-Symbicort-ads-that-endangered-patients-health.jpg)
AstraZeneca fined for misleading Symbicort ads that endangered patients’ health
In a startling turn of events, AstraZeneca finds itself entangled in a web of controversy as it faces stern scrutiny ...
![Harbinger Health cancer screening, Harbinger Health $140M VC round, Blood-based cancer screening platform, Harbinger Health startup company, Multi-cancer early detection, Harbinger Health launch plans, Harbinger Health technology,](https://pharmtales.com/wp-content/uploads/2023/09/Harbinger-Health-raises-140M-to-launch-its-blood-based-cancer-screening-platform.jpg)
Harbinger Health raises $140M to launch its blood-based cancer screening platform
Harbinger Health has secured substantial funding through a series B financing round, raising a total of $140 million to advance ...
![Karuna KarXT FDA approval, KarXT schizophrenia drug, Karuna biotech company, KarXT muscarinic receptors, KarXT novel mechanism of action, KarXT phase 3 trial results, KarXT safety and efficacy,](https://pharmtales.com/wp-content/uploads/2023/09/Karuna-submits-KarXT-a-novel-schizophrenia-drug-to-FDA-for-approval.jpg)
Karuna submits KarXT, a novel schizophrenia drug, to FDA for approval
Karuna Pharmaceuticals has taken a significant step towards gaining approval for its schizophrenia drug, KarXT, as it formally submitted its ...
![J&J Rybrevant combo, Rybrevant and lazertinib, Tagrisso lung cancer, EGFR-mutated NSCLC, Rybrevant vs Tagrisso trial, J&J lazertinib acquisition, Rybrevant first-in-class approval,](https://pharmtales.com/wp-content/uploads/2023/09/JJs-Rybrevant-combination-therapy-beats-AZs-Tagrisso-in-lung-cancer-trial.jpg)
J&J’s Rybrevant combination therapy beats AZ’s Tagrisso in lung cancer trial
In a highly anticipated head-to-head battle between Johnson & Johnson’s combination therapy and AstraZeneca’s Tagrisso as a first-line treatment for ...
![Merck KGaA Quris AI partnership, Quris drug toxicity prediction, Merck KGaA drug discovery, Quris AI startup, Merck KGaA Quris collaboration extension, Quris toxicity prediction platform, Merck KGaA AI deals,](https://pharmtales.com/wp-content/uploads/2023/09/Merck-KGaA-expands-AI-partnership-with-Quris-to-predict-drug-toxicity.jpg)
Merck KGaA expands AI partnership with Quris to predict drug toxicity
Merck KGaA continues to embrace the realm of artificial intelligence (AI), with a fresh development in its collaboration with Quris-AI. ...
![Bluebird Lonza gene therapies partnership, Zynteglo and Skysona manufacturing, Bluebird gene therapies for rare diseases, Lonza contract manufacturing services, Bluebird Zynteglo beta-thalassemia, Bluebird Skysona cerebral adrenoleukodystrophy, Bluebird Lonza collaboration agreement,](https://pharmtales.com/wp-content/uploads/2023/09/Bluebird-partners-with-Lonza-to-increase-production-of-its-gene-therapies-for-rare-diseases.jpg)
Bluebird partners with Lonza to increase production of its gene therapies for rare diseases
As bluebird bio takes flight with its high-priced gene therapies, the company is enhancing its manufacturing capabilities through a strategic ...
![Arcutis new CCO, Patrick Flanagan Incyte, Arcutis Zoryve marketing, Arcutis pipeline products, Arcutis dermatology company, Zoryve plaque psoriasis treatment, Arcutis upcoming approval,](https://pharmtales.com/wp-content/uploads/2023/09/Arcutis-hires-Incytes-former-CCO-to-lead-commercialization-of-Zoryve-and-pipeline-products.jpg)
Arcutis hires Incyte’s former CCO to lead commercialization of Zoryve and pipeline products
Arcutis Biotherapeutics, riding high on a dermatology approval and another on the horizon, has enlisted L. Todd Edwards as its ...
![Clario and CellCarta partnership, Digital pathology and biomarker services, Tissue and sample management in trials, Clario digital pathology platform, CellCarta biomarker services, Clinical trial data integration, Clinical trial workflow optimization,](https://pharmtales.com/wp-content/uploads/2023/09/Clario-and-CellCarta-join-forces-to-improve-tissue-and-sample-management-in-clinical-trials.jpg)
Clario and CellCarta join forces to improve tissue and sample management in clinical trials
Clinical trial technology firm Clario has embarked on a strategic partnership with CellCarta to revolutionize the management of tissue and ...
![Pharma’s digital content lacks credibility among HCPs, survey reveals](https://pharmtales.com/wp-content/uploads/2023/09/Pharmas-digital-content-lacks-credibility-among-HCPs-survey-reveals.jpg)
Pharma’s digital content lacks credibility among HCPs, survey reveals
A recent survey targeting healthcare professionals (HCPs) has unveiled a striking lack of trust in digital content originating from pharmaceutical ...
![GSK aims to boost HIV sales to £7B with new drugs and launches](https://pharmtales.com/wp-content/uploads/2023/09/GSK-aims-to-boost-HIV-sales-to-7B-with-new-drugs-and-launches.jpg)
GSK aims to boost HIV sales to £7B with new drugs and launches
GSK is charting an optimistic course for its HIV business, buoyed by the success of its long-acting antiretroviral therapy, Cabenuva. ...
![Big Pharma agrees to negotiate drug prices with Medicare: What does it mean for patients and taxpayers?](https://pharmtales.com/wp-content/uploads/2023/09/Big-Pharma-agrees-to-negotiate-drug-prices-with-Medicare_-What-does-it-mean-for-patients-and-taxpayers.jpg)
Big Pharma agrees to negotiate drug prices with Medicare: What does it mean for patients and taxpayers?
Following the recent disclosure by the Centers for Medicare & Medicaid Services (CMS) regarding the list of drugs slated for ...
![Deep Genomics unveils BigRNA, a powerful AI model for RNA biology and therapeutics](https://pharmtales.com/wp-content/uploads/2023/09/Deep-Genomics-unveils-BigRNA-a-powerful-AI-model-for-RNA-biology-and-therapeutics.jpg)
Deep Genomics unveils BigRNA, a powerful AI model for RNA biology and therapeutics
Deep Genomics is blending two groundbreaking technologies, artificial intelligence (AI) and RNA research, to explore the intricate world of RNA ...
![First Patient Receives BCI-Enabled Neurostimulator to Restore Arm Function](https://pharmtales.com/wp-content/uploads/2023/09/First-Patient-Receives-BCI-Enabled-Neurostimulator-to-Restore-Arm-Function.jpg)
First Patient Receives BCI-Enabled Neurostimulator to Restore Arm Function
Dutch medical device manufacturer Onward Medical has pioneered a groundbreaking approach to restoring arm and hand mobility in individuals who ...
![Hermes Pharma invests in user-friendly oral dosage forms production](https://pharmtales.com/wp-content/uploads/2023/09/Hermes-Pharma-invests-in-user-friendly-oral-dosage-forms-production.jpg)
Hermes Pharma invests in user-friendly oral dosage forms production
Hermes Pharma, a German Contract Development and Manufacturing Organization (CDMO), has announced a significant investment of 25 million euros ($26 ...
![Lilly secures Emgality’s future after judge invalidates Teva’s patents](https://pharmtales.com/wp-content/uploads/2023/09/Lilly-secures-Emgalitys-future-after-judge-invalidates-Tevas-patents.jpg)
Lilly secures Emgality’s future after judge invalidates Teva’s patents
A federal judge in Massachusetts has ruled in favor of Eli Lilly, overturning a $176.5 million jury verdict issued in ...